JSJean-Marie Saudubray

Jean-Marie Saudubray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jean-Marie Saudubray has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical approach to treatable inborn metabolic diseases: An introduction

    by J.‐M. Saudubray, F. Sedel, J. H. Walter

    Summary: In view of the major improvements in treatment, it has become increasingly important that in order for first‐line physicians not to miss a treatable disorder they should be able initiate a simple method of clinical screening, particularly in the emergency room. We present a simplified classification of treatable inborn errors of metabolism in three groups. Group 1 includes inborn errors of intermediary metabolism that give rise to an acute or chronic intoxication. It encompasses aminoacidopathies, organic acidurias, urea cycle disorders, sugar intolerances, metal disorders and porphyrias. Clinical expression can be acute or systemic or can involve a specific organ, and can strike in the neonatal period or later and intermittently from infancy to late adulthood. Most of these disorders are treatable and require the emergency removal of the toxin by special diets, extracorporeal procedures, cleansing drugs or vitamins. Group 2 includes inborn errors of intermediary metabolism that affect the cytoplasmic and mitochondrial energetic processes. Cytoplasmic defects encompass those affecting glycolysis, glycogenosis, gluconeogenesis, hyperinsulinisms, and creatine and pentose phosphate pathways; the latter are untreatable. Mitochondrial defects include respiratory chain disorders, and Krebs cycle and pyruvate oxidation defects, mostly untreatable, and disorders of fatty acid oxidation and ketone bodies that are treatable. Group 3 involves cellular organelles and includes lysosomal, peroxisomal, glycosylation, and cholesterol synthesis defects. Among these, some lysosomal disorders can be efficiently treated by enzyme replacement or substrate reduction therapies. Physicians can be faced with the possibility of a treatable inborn error in an emergency, either in the neonatal period or late in infancy to adulthood, or as chronic and progressive symptoms – general (failure to thrive), neurological, or specific for various organs or systems. These symptoms are summarized in four tables. In addition, an extensive list of medications used in the treatment of inborn errors is presented.


  • Δ1-pyrroline-5-carboxylate synthase deficiency: neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonaemia and reduced ornithine, citrulline, arginine and proline

    by Matthias R. Baumgartner, Daniel Rabier, Marie-Cécile Nassogne, Jean-Louis Dufier, Jean-Paul Padovani, Pierre Kamoun, David Valle, Jean-Marie Saudubray

    Δ1-pyrroline-5-carboxylate synthase (P5CS) catalyses the reduction of glutamate to Δ1-pyrroline-5-carboxylate, a critical step in the biosynthesis of proline, ornithine and arginine. Recently, we reported a newly recognised inborn error due to deficiency of P5CS in two sibs, one presenting at birth with hypotonia, dysmorphic signs, pes planus and clonic seizures. Both developed progressive neurodegeneration and peripheral neuropathy, joint laxity, skin hyperelasticity and bilateral subcapsular cataracts. Their metabolic phenotype includes mild hyperammonaemia, hypo-ornithinaemia, hypocitrullinaemia, hypo-argininaemia and hypoprolinaemia. Incorporation of 3H-proline into protein was deficient in fibroblasts incubated with 3H-glutamate. Both patients are homozygous for the missense mutation R84Q in P5CS. Here, we describe the clinical phenotype of the sibs in detail and show that a relative deficiency of urea cycle intermediates (ornithine, citrulline and arginine) during fasting periods results in a paradoxical hyperammonaemia. Furthermore, we show the results of ornithine loading tests and indirect enzyme studies corroborating the biological significance of the defect in P5CS in vivo. Conclusion:The metabolic phenotype of Δ1-pyrroline-5-carboxylate synthase deficiency is easily missed. The combination of low levels of ornithine, citrulline, arginine and proline plus a tendency to hyperammonaemia or one of the above together with a clinical phenotype of neurodegeneration with peripheral neuropathy and/or cataracts and connective tissue manifestations should suggest this disorder. Early recognition would allow a therapeutic trial with citrulline and proline.


  • Clinical approach to inherited metabolic disorders in neonates: an overview

    by J.M. Saudubray, M.C. Nassogne, P. de Lonlay, G. Touati


    • 1 December 2001
      • p. 338s-346s

    [Hereditary metabolic causes of stroke and pseudo-stroke in adulthood].

    by M C Nassogne, G Touati, C Beyler, J M Saudubray

    Metabolic diseases are a rare cause of strokes. However, prevention and treatment are available for some of them. This work describes some metabolic diseases generating strokes by disturbing directly vascular function (homocysteine disorders, Fabry disease, congenital defects of glycosylation) and those for which clinical presentation is similar to a stroke (urea cycle disorders, branched-chain organic acidurias, mitochondrial diseases).

    • 1 December 2001
      • p. 347s-355s

    [Homocystinuria in adulthood].

    by I Quéré, B Simorre, M Ruivard, C Le Hello, F Parrot, J L Mégnien, G Touati, J F Chassé, J M Saudubray, J Zittoun

    Homocystinuria is a genetically determined inborn error of the methionine amino acid pathway characterized by increased plasma homocysteine. In its major form, homocystinuria, is due to cystathionine beta synthase deficiency. Treatment of these adulthood patients lead physicians to call up on the skilled advices of pediatricians. But prevention and treatment of age related vascular and osteoporotic complications are still to be evaluated.

    • 1 July 2001
      • Vol. 90  (7) , 827-8

    5-Oxoprolinuria: a cause of neonatal metabolic acidosis.

    by D Mitanchez, D Rabier, M Mokhtari, X Durrmeyer, A Menget, A Larsson, J M Saudubray


    • 1 May 2001
      • Vol. 94  (5) , 531-3

    [A rare cause of cardiomyopathy in childhood: propionic acidosis. Three case reports].

    by P Ou, G Touati, A Fraisse, D Sidi, J Kachaner, J M Saudubray, D Bonnet

    Dilated cardiomyopathy is a rare and unrecognised complication of propionic acidosis. It usually progresses to chronic cardiac failure with a poor prognosis. The authors report three cases of cardiomyopathy due to this condition. One of the children underwent liver transplantation which cured the cardiac complication.


    • 1 May 2000
      • Vol. 61  (2) , 139

    [Molecular basis of hyperinsulinisms].

    by P De Lonlay-Debeney, J J Robert, J M Saudubray

    • 1 January 1998
      • Vol. 182  (1) , 131

    [A new inherited metabolic disease: delta1-pyrroline 5-carboxylate synthetase deficiency].

    by P Kamoun, B Aral, J M Saudubray

    Delta 1-pyrroline 5-carboxylate synthetase (P5C synthetase) catalyzes the ATP and the NAD(P)H-dependent conversion of L-glutamate to glutamate semialdehyde (GSA) which is the metabolic precursor for proline biosynthesis. We described in two siblings a paradoxical hyperammonemia with hypoprolinemia and hypoornithinemia associated to bilateral cataract, mental retardation, joint laxity and skin hyperelasticity. We cloned human P5C synthetase-cDNA by database cloning strategy: this cDNA has an open reading frame of 2,385 bases coding for a polypeptide of 795 amino acids. Both patients are homozygous for an L396S substitution, this amino acid being highly conserved across species. This is the first report of a P5C synthetase deficiency in human.